Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, and Sarcoma Diagnosis and Treatment.
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer
Converging and evolving immuno-genomic routes toward immune escape in breast cancer
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent<sup>177</sup>Lu-Labeled Radiohapten
Anatomic position determines oncogenic specificity in melanoma
IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
Insights into pathogenesis of fatal COVID‐19 pneumonia from histopathology with immunohistochemical and viral RNA studies
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity
Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors
BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets
<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement
Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST
Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions
Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and donor lymphocyte infusions